INNV — InnovAge Holding Corp.

InnovAge Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $236.1 million, a 15% increase year-over-year.
• Adjusted EBITDA: $17.6 million, more than double compared to Q1 2025.
• Net Income: $7.7 million, compared to a net loss of $5.7 million in Q1 2025.
• Census Growth: Reached an all-time high of 7,890 participants, up nearly 2% quarter-over-quarter.
• Center-Level Contribution Margin: $51.4 million, representing 21.8% of revenue, up from 18.6% in the previous quarter.
• Cash and Equivalents: $67.1 million, with total debt at $71.5 million.

2. Strategic Updates and Business Highlights

• InnovAge reported strong medical cost management and better-than-expected census growth, particularly in Florida.
• The company emphasized its unique PACE model, which integrates care and offers better outcomes for frail seniors compared to traditional Medicare Advantage plans.
• Leadership changes include the appointment of Dr. Paul Taheri as Chief Medical Officer and Meredith Delk as Chief Administrative Officer, aimed at strengthening operational capabilities.
• The company is focused on improving care coordination and reducing costs through in-house services, including pharmacy and hospice.

3. Forward Guidance and Outlook

• InnovAge reaffirmed its fiscal year 2026 guidance, projecting:
  • Ending census of 7,900 to 8,100 participants.
  • Total revenue between $900 million and $950 million.
  • Adjusted EBITDA in the range of $56 million to $65 million.
  • Anticipated de novo losses of $13.4 million to $15.4 million for the fiscal year.
• The company cautioned that first-quarter results should not be seen as indicative of full-year performance due to seasonality and Medicaid redetermination impacts.

4. Bad News, Challenges, or Points of Concern

• The operating environment remains challenging with declining reimbursement levels in Medicare Advantage and Medicaid managed services.
• Increased regulatory scrutiny and higher medical service utilization are concerns for the broader value-based care model.
• Leadership transitions, while seen as opportunities, could pose risks if not managed effectively.
• The company noted potential lumpiness in performance due to ongoing Medicaid eligibility issues and seasonal cost trends.

5. Notable Q&A Insights

• Management discussed the competitive landscape, noting an increase in Special Needs Plans but expressed confidence in PACE's unique value proposition.
• Questions about cost trends revealed that while external provider costs increased, they were offset by improved utilization and in-house pharmacy efficiencies.
• The team acknowledged that while they have made progress in clinical initiatives, they estimate they are only 50% toward fully standardizing processes to optimize care delivery.
• The leadership emphasized the importance of reducing variations in care and enhancing clinical guidelines to improve decision-making across centers.

Overall, InnovAge demonstrated a strong start to fiscal 2026 with significant revenue growth and improved profitability, while also navigating challenges in the healthcare landscape and preparing for future growth through strategic initiatives and leadership enhancements.